A phase 2 clinical trial of trabectedin in ovarian cancer patients, showed a significant depletion of blood monocytes, as well as a reduction in CCL2 levels, in TAMs and ovarian tumor cells [67]. This evidence concerns the gene CCL2 and ovarian carcinoma.